Aker BioMarine

Prospectus • Jun 16, 2025

Aker BioMarine ASA – Base prospectus approved for listing of bonds

Aker BioMarine ASA – Base prospectus approved for listing of bonds

The Financial Supervisory Authority of Norway has on 16 June 2025 approved the base prospectus with appendices prepared by Aker BioMarine ASA in connection with the listing of the company's most recent bond issue on the Oslo Stock Exchange:

ISIN NO0013326025 - FRN Senior Secured Bond Issue 2024/2027

The prospectus with appendices and Final Terms is available on the company's website: https://www.akerbiomarine.com/investor

Lysaker, 16 June 2025

Aker BioMarine ASA

For further information, please contact

Christopher Robin Vinter, VP IR & Corporate Finance

Mobile: +47 911 60 820

Email: Christopher.vinter@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to MAR Article 19 and Section 5-12 of the Norwegian Securities Trading Act.

About Aker BioMarine:

Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, Revervia, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.